ArticleMolecular biology reports2026
Serum TP53 autoantibodies as a non-invasive diagnostic biomarker for canine mammary tumours: comparative insights from human and experimental rat model.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCanine mammary tumours (CMTs) represent a valuable spontaneous model for human breast cancer, as both share comparable pathological features and frequent alterations in the TP53 pathway. Although TP53 involvement in tumour development is well established, the diagnostic relevance of circulating TP53 autoantibodies in dogs remains insufficiently characterized. This study evaluated the diagnostic utility of TP53 autoantibodies in CMTs using a recombinant TP53-based immunoassay, supported by comparative analyses in human and experimental animal models. METHODS AND
resultsRecombinant canine TP53 protein was expressed and employed in indirect ELISA and dot blot assays to detect serum TP53 autoantibodies in 141 canine serum samples, including sera from dogs with mammary tumours and healthy controls. Comparative evaluation included serum samples from 100 human subjects (50 breast cancer patients and 50 healthy individuals) as well as a longitudinal N-nitroso-N-methylurea (NMU)-induced rat mammary tumour model to examine the temporal appearance of autoantibodies before and during tumour development.TP53 autoantibodies were detected in 60.0% of dogs with mammary tumours and were absent in healthy controls (p < 0.0001), demonstrating high diagnostic accuracy (AUC 0.9587; sensitivity 60%; specificity 100%). Comparable trends were observed in human breast cancer sera (AUC 0.8956; sensitivity 52%; specificity 98%). Notably, longitudinal analysis of the NMU-induced rat model revealed the presence of TP53 autoantibodies before overt tumour formation, highlighting their potential role in early cancer detection.
conclusionsThese findings support recombinant TP53-based ELISA as a sensitive, specific, & non-invasive diagnostic approach and identify circulating TP53 autoantibodies as promising early biomarkers in comparative and translational oncology.
Indexed as
Identifiers
42446626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.